A randomised phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement
J Am Acad Dermatol 2024;91:1150–7 doi: 10.1016/j.jaad.2024.07.1521
Lebwohl et al. investigated the efficacy and safety of risankizumab compared with placebo for treating palmoplantar psoriasis. At Wk16, significantly more patients receiving risankizumab achieved palmoplantar Investigator’s Global Assessment (ppIGA) 0/1 and PPASI75. The results were sustained through Wk52 with no new safety signals.